CPA
AMRX icon

Capital Performance Advisors’s Amneal Pharmaceuticals AMRX Stock Holding History

Capital Performance Advisors’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-163
Closed -$1.36K – 299
2024
Q3 		$1.36K Buy
+163
New +$1.27K ﹤0.01% 1759

Other funds holding AMRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Capital Performance Advisors's AMRX Position: Q4 2024 in Review

Capital Performance Advisors sold out of Amneal Pharmaceuticals (AMRX) in Q4 2024, closing a stake of 163 shares — an estimated $1.36K sold.

Capital Performance Advisors first reported a position in AMRX in Q3 2024 and held it in 1 quarter. The position peaked at $1.36K in Q3 2024. 199 funds tracked by Wall St. Rank hold AMRX as of Q4 2024.

  • Capital Performance Advisors reported no remaining Amneal Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 163 Amneal Pharmaceuticals shares in Q4 2024, an estimated $1.36K.
  • Capital Performance Advisors first reported a position in Amneal Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Amneal Pharmaceuticals position peaked at $1.36K in Q3 2024.
  • 199 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.